AstraZeneca and Inhalation Sciences begin research collaboration using PreciseInhale
Inhalation Sciences and AstraZeneca have entered into a collaboration to use PreciseInhale for the evaluation of inhaled drugs.
PreciseInhale is recognized as exceptionally innovative by several pioneering groups in the inhalation community. In collaborating with Inhalation Sciences, AstraZeneca is exploring new opportunities in inhalation R&D.
ISAB CEO Fredrik Sjövall: “AstraZeneca is a truly forward-looking company with a clear strategy of being scientific leaders. We’ve developed PreciseInhale in close collaborations like these from the beginning. We thrive on exacting feedback and tough scientific demands—and we know we can expect that from the team at AstraZeneca in Gothenburg.”
Read more about AstraZeneca and Inhalation Sciences collaboration here.